REFERENCES
1. Muenzer J, Burton BK, Harmatz P, et al. An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II. N Engl J Med. 2026;394:39-50.
2. Denali Therapeutics. Press Release. Denali therapeutics announces U.S. FDA approval of AVLAYAHTM (tividenofusp alfa-eknm) for treatment of hunter syndrome (MPS II). 2026. Available from: https://investors.denalitherapeutics.com/node/11606/pdf [Last accessed on 23 Sep 2026].
3. U.S. Food and Drug Administration. FDA news release. FDA approves drug to treat neurologic manifestations of hunter syndrome. 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome [Last accessed on 23 Sep 2026].
4. Kariolis MS, Wells RC, Getz JA, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12:eaay1359.
5. Arguello A, Mahon CS, Calvert ME, et al. Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme. J Exp Med. 2022;219:e20211057.
6. Fukatsu T, Morio H, Furihata T, Sonoda H. Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro. Front. Drug Deliv. 2023;3:1082672.
7. Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial. Mol Ther. 2019;27:456-64.
8. Okuyama T, Eto Y, Sakai N, et al. A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2021;29:671-9.
9. Bonvicini G, Singh S, Sandersjöö L, Sehlin D, Syvänen S, Andersson KG. The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo. Fluids Barriers CNS. 2025;22:36.
10. Bien-Ly N, Yu YJ, Bumbaca D, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211:233-44.
11. Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49-60.
12. Muenzer J, Burton BK, Harmatz P, et al. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2/3 randomized study. Mol Genet Metab. 2022;137:127-39.
13. Argueta C, Brekk OR, Wang S, et al. A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase. Mol Genet Metab. 2025;144:109055.
14. Saikia S, Celik B, Khan S, Tomatsu S. The complementary strength of the AAV9 gene therapy in hematopoietic stem cells transplanted into MPS IVA mice. Mol Genet Metab. 2026;147:109607.
15. Harmatz P, Giugliani R, Martins AM, et al. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: a phase 1/2 trial. Mol Ther. 2024;32:609-18.
16. Kida S, Koshimura Y, Yoden E, et al. Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice. Mol Ther Methods Clin Dev. 2023;29:439-49.
17. Yamamoto R, Yoden E, Tanaka N, et al. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Mol Genet Metab Rep. 2021;27:100758.
18. Arguello A, Meisner R, Thomsen ER, et al. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. JCI Insight. 2021;6:e145445.
19. Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12:eaay1163.
20. George K, Riley R, Zhou S, et al. Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice. Mol Ther Methods Clin Dev. 2025;33:101547.
21. Boado RJ, Lu JZ, Hui EK, Pardridge WM. Reduction in brain heparan sulfate with systemic administration of an IgG trojan horse-sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse. Mol Pharm. 2017;15:602-8.
